Therini Bio, Inc.

($36M in Series A Funding)

Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies for inflammatory neurodegenerative and retinal diseases, announced the close of a $36M Series A financing round

The funding round was co-led by Dementia Discovery Fund, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., Sanofi Ventures, and SV Health Investors’ Impact Medicine Fund. New investor Eli Lilly and Company participated in the round, alongside existing investors Alzheimer’s Drug Discovery Foundation (ADDF), Dolby Family Ventures, and Foundation for a Better World. The Series A funding brings the total amount raised since inception to $62M.

Popular post

ShiftPixy: Redefining the Gig Economy with Innovative Workforce Solutions
In an era where flexibility is king and gig jobs are becoming...
Shaping the Future: How Family Offices are Leading the $84 Trillion Wealth Transfer
In the dynamic landscape of today’s global finance, Family...
Family Office Growth News — March 2024 Edition
Welcome to the March 2024 Edition of Family Office Growth News!

Arondight Advisors
© 2024 All Rights Reserved

Subscribe to Newsletter